• LAST PRICE
    4.8900
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    4.0000/ 97
  • Ask / Lots
    7.8200/ 2
  • Open / Previous Close
    0.0000 / 4.8900
  • Day Range
    ---
  • 52 Week Range
    Low 3.5100
    High 9.9600
  • Volume
    ---
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Tuesday's close: 4.8
TimeVolumeXBIT
09:32 ET46004.575
09:36 ET6474.675
09:41 ET3004.705
09:45 ET1004.705
09:50 ET8504.775
09:52 ET1004.725
09:54 ET3004.725
09:57 ET5004.735
09:59 ET1004.735
10:03 ET4464.715
10:10 ET1004.715
10:12 ET1004.715
10:17 ET3004.79
10:19 ET2004.75
10:26 ET1004.75
10:28 ET6004.69
10:32 ET26954.63
10:37 ET14004.76
10:39 ET3004.62
10:44 ET1004.65
10:53 ET17244.71
10:55 ET8024.71
10:57 ET53484.77
11:00 ET21054.77
11:02 ET5004.855
11:06 ET5004.845
11:08 ET2004.79
11:09 ET2004.79
11:11 ET1004.855
11:13 ET2004.79
11:15 ET7004.78
11:18 ET1004.72
11:20 ET20004.84
11:24 ET1004.85
11:26 ET20184.795
11:27 ET13154.81
11:29 ET4004.885
11:31 ET1004.885
11:33 ET1004.885
11:36 ET1004.83
11:38 ET25004.88
11:40 ET1004.815
11:42 ET4174.73
11:44 ET2004.67
11:47 ET10134.84
11:49 ET11004.84
11:51 ET5004.78
11:56 ET45214.85
11:58 ET2004.85
12:00 ET1004.88
12:02 ET9674.87
12:03 ET1004.85
12:05 ET1004.85
12:07 ET2794.87
12:09 ET5144.85
12:12 ET1004.85
12:14 ET4004.85
12:16 ET8004.85
12:18 ET1004.85
12:20 ET2004.85
12:21 ET10074.81
12:23 ET4004.75
12:25 ET3004.66
12:27 ET1004.66
12:30 ET12004.7
12:32 ET1004.76
12:34 ET8264.7
12:36 ET1004.71
12:38 ET1004.71
12:39 ET1004.77
12:41 ET2004.71
12:45 ET1004.705
12:48 ET5004.76
12:50 ET2004.685
12:52 ET2004.69
12:54 ET1004.68
12:56 ET2004.75
12:57 ET44734.74
12:59 ET11004.79
01:01 ET3004.755
01:03 ET7004.825
01:06 ET3004.8375
01:08 ET8504.79
01:10 ET13124.85
01:14 ET2004.835
01:15 ET7004.8
01:17 ET1004.8
01:19 ET1004.855
01:21 ET1004.805
01:24 ET2004.805
01:26 ET8514.83
01:28 ET2004.82
01:30 ET4004.82
01:32 ET2004.865
01:33 ET3004.86
01:35 ET13004.85
01:37 ET1004.8
01:39 ET2004.81
01:42 ET1004.81
01:44 ET1004.81
01:46 ET1004.825
01:48 ET4004.85
01:50 ET3004.875
01:51 ET2004.88
01:53 ET4004.855
01:55 ET1004.85
01:57 ET1004.85
02:00 ET3004.88
02:02 ET5004.87
02:04 ET1004.9
02:06 ET1004.9
02:08 ET3004.91
02:09 ET35805
02:11 ET5165
02:13 ET5754.97
02:15 ET2004.975
02:18 ET1005
02:24 ET4475.05
02:27 ET1005.13
02:36 ET4005.15
02:40 ET1655.15
02:49 ET1005.16
02:54 ET4005.14
02:56 ET2005.13
02:58 ET3215.13
03:00 ET2375.12
03:02 ET1005.085
03:03 ET1005.12
03:12 ET17004.99
03:16 ET7205.055
03:25 ET1005.05
03:32 ET2005.03
03:34 ET26005.025
03:36 ET8095.08
03:38 ET10145.12
03:39 ET7945.14
03:41 ET11805.12
03:43 ET4005.09
03:45 ET1005.1
03:48 ET1005.07
03:50 ET12005.01
03:52 ET2005.01
03:54 ET33245.03
03:56 ET19005.02
03:57 ET15975.01
03:59 ET45444.89
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesXBIT
XBiotech Inc
146.2M
-4.8x
---
United StatesCMPX
Compass Therapeutics Inc.
145.8M
-3.0x
---
United StatesFBLG
Fibrobiologics Inc
146.9M
-4.3x
---
United StatesIVVD
Invivyd Inc
144.4M
-0.6x
---
United StatesCNTX
Context Therapeutics Inc
148.5M
-1.5x
---
United StatesINMB
INmune Bio Inc
144.2M
-3.8x
---
As of 2024-06-27

Company Information

XBiotech Inc. is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies for treating a variety of diseases, such as inflammatory conditions like rheumatology, infectious disease, cardiovascular disease and cancer. The Company's True Human monoclonal antibodies are derived from human donors that mount a natural human immune response. The Company is focused on therapies that block a potent substance, known as interleukin-1 alpha (IL-1a), that mediates a number of pathophysiological processes including tissue breakdown (i.e. synovium, cartilage, bone), paraneoplastic angiogenesis and tumor stroma remodeling, formation of blood clots, malaise, muscle wasting and general inflammation. It has various candidate products including Natrunix. It has a clinical-stage therapeutic for methicillin resistant Staphylococcus aureus (MRSA), and several pre-clinical-stage therapeutics, including an oral delivery antibody therapeutic for colon infection by C. difficile.

Contact Information

Headquarters
5217 WINNEBAGO LANEAUSTIN, TX, United States 78744
Phone
512-386-2900
Fax
---

Executives

Chairman of the Board, President, Chief Executive Officer, Founder
John Simard
Director of Finance
Angela Hu
Chief Scientific Officer
Sushma Shivaswamy
Lead Independent Director
Jan-Paul Waldin
Independent Director
Peter Libby

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$146.2M
Revenue (TTM)
$0.00
Shares Outstanding
30.5M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.38
EPS
$-1.01
Book Value
$7.19
P/E Ratio
-4.8x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.